印度扩大了受价格管控的基要抗癌药物名单，力求使这个价值26亿美元的肿瘤治疗药物市场的治疗费用更加亲民。
India has expanded the list of essential anti-cancer drugs that will be subject to price controls, as it seeks to make treatments in the $2.6 billion oncology market more affordable.
化学和化肥部周六发表声明称，多达137种经认定的非列管抗癌药物的价格将下调多达70%。
Prices of as many as 137 identified non-scheduled anti-cancer drugs will be reduced by up to 70%, according to a statement from the Ministry of Chemicals and Fertilizers on Saturday.
该部表示，这些药物包括用于20种癌症的免疫疗法药物，以及用于乳腺癌、前列腺癌、结肠癌、卵巢癌和宫颈癌的药物。修改后的价格将于11月9日起生效。
The medicines include immunotherapy drugs used for 20 types of the disease, as well as for breast, prostate, colon, ovary and cervical cancer, the ministry said. The revised prices will become effective from Nov. 9.
根据此前的一份声明，这些药物的利润率将被限制在最高零售价的30%以内，每年可为癌症患者节省多达250亿卢比（约合2.63亿美元）。
Margins on these drugs will be limited to 30% of the maximum retail price, saving cancer patients as much as 25 billion rupees ($263 million) each year, according to an earlier statement.
此举反映出印度当局正在加大力度遏制药物的高额加价，并降低患者的医疗成本，尤其是医院的医疗成本。在接受治疗的人群中，印度约有44%的整体医疗开支由患者自付，在主要经济体中居于最高之列。
The move reflects a widening push by Indian authorities to rein in steep markups on medicines and reduce healthcare costs for patients, particularly at hospitals. About 44% of India’s overall healthcare spending is paid out of pocket for those treated, among the largest in major economies.
最新的降价措施扩大了2019年对42种抗癌药物实施的管控，当时这些药物的价格最高降幅达到了90%。
The latest cuts expand on controls introduced in 2019 on 42 anti-cancer medicines, which reduced prices by up to 90%.
印度制药联盟秘书长苏达山·杰恩表示：“随着国内癌症发病率的不断增加，获得价格合理、质量有保障的药物至关重要。”
“With the increasing incidence of cancer in the country, access to affordable, quality-assured medicines is critical,” according to Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance.
杰恩称，新措施将优化肿瘤产品的价格，同时为渠道合作伙伴留出充足的利润空间。
The new measures would optimize prices for oncology products, while allowing for adequate margin to channel partners, Jain said.
价格上限将统一适用于品牌药和仿制药、国产和进口产品，以及专利药和非专利药。
The cap will apply uniformly across branded and generic formulations, domestic and imported products, and both patented and non-patented medicines.
上个月，由于最高法院对救命抗癌药物的高额加价提出质疑，市场担心高利润率的药房收入可能受到威胁，印度医疗保健类股票的市值应声暴跌。
Indian healthcare stocks plunged in market value last month on concerns that high-margin pharmacy revenue may come under threat after the top court questioned steep markups on lifesaving cancer drugs.
据印度报业托拉斯报道，印度最高法院要求联邦政府调查有关医院迫使其患者从自身或指定药房购买药物的指控，尤其是当这些药物带有高额利润时。印度报业托拉斯援引法院的话称，癌症药物高达10倍的加价是“一场大屠杀”，并询问是否应对所有药物实行统一的16%利润率。
India’s Supreme Court asked the federal government to probe allegations that hospitals make patients purchase medicines from their own or designated pharmacies, especially when the drugs carry a steep margin, the Press Trust of India reported. A markup of as much as 10 times on cancer drugs is “carnage,” PTI quoted the court as saying, asking whether there should be a uniform 16% margin on all medicines.
野村证券在10月9日的一份报告中估计，印度的平均药价将下降约50%，对于肿瘤业务占比较高的公司而言，近期的影响可能会更为明显。
Nomura estimates average drug prices in India will fall by about 50%, with the near-term impact likely to be more pronounced for companies with a high oncology exposure, it said in an Oct. 9 note.
这种审查可能会影响大型私立医院，在这些医院中，药品和辅助服务是收入的关键组成部分。保健全球企业有限公司的收入有72%来自肿瘤学，而马克斯医疗保健研究所大约占24%，阿波罗医院企业有限公司和福蒂斯医疗保健有限公司大约占16%。
The scrutiny could affect large private hospitals, where medicines and ancillary services form a key component of revenues. HealthCare Global Enterprises Ltd. derives 72% of its revenue from oncology, while Max Healthcare Institute Ltd. gets about 24% and Apollo Hospitals Enterprise Ltd. and Fortis Healthcare Ltd. about 16%.